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Abstract 
Purpose: Multidrug resistance (MDR) remains one of the most significant obstacles in 
breast cancer treatment, and this process often involves dysregulation of a great 
number of microRNAs (miRNAs). Some miRNAs are indicators of drug resistance 
and confer resistance to chemotherapeutic drugs, although our understanding of this 
complex process is still incomplete. 
Methods: We have used a combination of miRNA profiling and real-time PCR in two 
drug resistant derivatives from MCF-7 and Cal51 cells. Experimental modulation of 
miR expression has been obtained by retroviral transfection. Taxol and doxorubicin 
IC50 values were obtained by short-term drug sensitivity assays. Apoptosis was 
determined by flow cytometry after annexin V staining, by caspase 3/7 and caspase 9 
activity assays and the levels of apoptosis related proteins bcl-2 and bax by real-time 
PCR and western blot. Mir target was studied using transient transfection of luciferase 
constructs with the 3'-untranslated regions (UTR) of target mRNAs. Small interfering 
RNA-mediated genetic knock-down was performed in multidrug resistance cells and 
its modulatory effect on apoptosis examined. The effect of miRNA on tumorigenicity 
and tumor drug response was studied in mouse xenografts. 
Results: MiRNA profiling of two drug resistant breast cancer cell models indicated 
that miR-218 was down-regulated in both MCF-7/A02 and CALDOX cells. Ectopic 
expression of miR-218 resensitized both drug resistant cell lines to doxorubicin and 
taxol due to an increase in apoptosis. MiR-218 binds survivin (BIRC5) mRNA 3'-
UTR and down-regulated reporter luciferase activity. Experimental down-regulation 
of survivin by RNA interference in drug resistant cells did mimic the sensitization 
observed when miRNA-218 was up-regulated. In addition, resensitization to taxol was 
also observed in mouse tumor xenografts from cells over-expressing miR-218.  
Conclusions: MiR-218 is involved in the development of multidrug resistance in 
breast cancer cells via targeting survivin and leading to evasion of apoptosis. 
Targeting miR-218 and survivin may thus provide a potential strategy for reversing 
drug resistance in breast cancer. 
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Introduction 
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer 
death in females worldwide [1]. Current treatment strategies for breast cancer include 
surgery, radiotherapy and a variety of chemotherapeutic approaches using traditional 
non-targeted drugs, such as epirubicin, hormonal therapy, such as tamoxifen, and 
targeted drugs, such as herceptin. However, multidrug resistance (MDR) remains a 
major obstacle to the success of cancer chemotherapy, resulting in relapse and 
progression in a high proportion of breast cancer patients. MDR involves genetic and 
epigenetic dysregulation of a wide range of genes and may be caused by drug efflux 
transporters such as P-glycoprotein [2], breast cancer resistant protein (BCRP) 
or multiple resistance protein-1 (MRP1). In addition, inactivation by detoxification 
enzymes, the altered expression of pro-apoptosis and tumor suppressor genes, or the 
increased activity of DNA repair mechanisms are frequently involved [3,4]. Recent 
evidence indicates that microRNAs (miRNAs) regulate these processes [5,6]. 
 MiRNAs are a class of highly conserved, short, non-protein-coding small 
RNAs, usually 18-25 nucleotides in length that negatively regulate gene expression by 
repressing translation or cleaving RNA transcripts in a sequence-specific manner. 
MiRNAs regulate the biology of cancer cells, including their chemosensitivity [7,8]. 
Some miRNAs are indicators of drug resistance and confer resistance to a variety of 
chemotherapeutic drugs [9,10,11]. MiR-218 is expressed in several carcinomas and 
plays critical roles in carcinogenesis, cancer proliferation and cancer metastasis. Its 
down-regulation has been reported in several human malignancies, including cervical, 
gastric and colon cancer [12-15].  In breast cancer, BRCA1 and HoxB3 mRNAs are 
direct targets of miR-218 [16,17]. However, the functional role of miR-218 in breast 
cancer chemosensitivity remains to be characterized. 
 In this study we present  the miRNA signature of multidrug resistant MCF-7 
cells and found that miRNA 218 is also down-regulated in drug resistant cells derived 
from another breast cancer cell line, Cal51. Ectopic expression of miRNA-218 
resensitized both drug resistant cell lines to doxorubicin and taxol due to an increase 
in apoptosis. We show that miRNA-218 binds survivin mRNA 3'-UTR and that 
experimental down-regulation of survivin by RNA interference in drug resistant cells 
mimics the sensitization observed when miRNA-218 is up-regulated. Moreover, 
resensitization to taxol was also observed in mouse tumor xenografts from cells over-
expressing miR-218. Targeting miR-218 and survivin may thus provide a potential 
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strategy for reversing drug resistance in breast cancer cells. 
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Materials and methods 
 
Cell lines 
 
The human breast cancer cell lines MCF-7 and Cal51 and their drug resistant 
derivatives, MCF-7/ADR and CALDOX, have been described previously [5, 18]. 
Cells were cultured in low glucose (1 g/L) Dulbecco’s modified Eagle’s medium 
(DMEM, Sigma Aldrich, St Louis, MO, USA) supplemented with 10% (v/v) fetal calf 
serum and 500 units/ml penicillin, 500 μg/ml streptomycin and 10 mM L- glutamine 
(Sigma Aldrich, St Louis, MO, USA). The drug resistant phenotype was maintained 
by the addition of 2 μM doxorubicin for MCF-7/A02 and 0.2 μM for CALDOX. 
Doxorubicin and taxol were purchased from Sigma-Aldrich (St Louis, MO, USA).  
 
Plasmids, oligonucleotides and cell transfection 
 
Lentivirus particles carrying miR-218 cloned into pGLV2-U6-Puro and packaging 
plasmid mix were purchased from GenePharma (Shanghai, China). Lentiviral 
particles were filtered through 0.45 μm cellulose acetate filters and supplemented with 
8 μg/mL polybrene (Sigma-Aldrich, St Louis, MO, USA) prior to adding to recipient 
cells. Puromycin (1 μg/ml; Sigma-Aldrich) was added 96 hours after infection to 
recipient cells for selection of stable transgene expression [18]. A plasmid (pMir-
Target) carrying the survivin 3’-UTR downstream from a luciferase gene was 
purchased from Life Technologies (Grand Island, NY, USA). Cells (5x10
5
) were 
transiently transfected with 2 μg pMir-Target and 50 ng phRGTK (expressing Renilla 
luciferase to normalize for transfection efficiency; Promega, Madison, WI, USA) 
using lipofectamine 3000 (Life Technologies, Grand Island, NY, USA) following 
manufacturer’s recommendations. Luciferase activity was measured 48 h after 
transfection, in a GloMax
TM
 20/20 Luminometer (Promega, Madison, WI, USA) 
essentially as described [19]. A proprietary survivin siRNA was purchased from 
GenePharma (Shanghai, China). A siRNA (scrambled), comprising the same 
nucleotides as in survivin siRNA but in randomized order, was used as negative 
control and was also designed and synthesized by GenePharma. The scrambled 
sequence have no significant homology to any known human gene sequences in the 
GenBank database. Cells (3x10
5
) were transfected with 40 nM siRNA  and 
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lipofectamine 3000 (Life Technologies, Grand Island, NY, USA) following 
manufacturer’s recommendations. The effects of siRNA on survivin expression were 
examined 48 h after transfection at RNA level and 72 h after transfection at protein 
level. 
 
Cell viability analysis 
 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were 
performed to evaluate the cell growth inhibitory effect in response to drug treatments 
and were used to determine the concentration of drug that inhibited cell growth by 
50% (IC50) after 3 days of treatment [20].  
 
Drug resistance clonogenic assay 
 
Cells (2×10
5
 per well of a 6-well plate) were treated with a single dose of doxorubicin 
(15 μM for MCF-7/A02 and 1 μM for CALDOX), or taxol (0.25 μM for MCF-7/A02 
and 2.5 nM for CALDOX) for 1 week. Resistant clones were fixed with 4% 
paraformaldehyde and stained with 0.2% crystal violet and counted. Crystal violet 
retained in the cells was quantified by solubilization with 0.5% acetic acid and 
measurement of optical density at 592 nm [19]. 
 
Gene expression analysis 
 
For mRNA detection from cells, 2 μg total RNA (isolated using a miRCURY RNA 
isolation kit, Exiqon, Vedbaek, Denmark) was reverse transcribed with RNase H
+
 
MMLV reverse transcriptase (iScript cDNA synthesis kit, Bio-Rad, Hercules, CA, 
USA) and real-time quantitative PCR was performed on an ABI Prism 7900 detection 
system (PerkinElmer Life Sciences, Waltham, MA, USA) using SYBR-Green 
(Promega, Madison, WI, USA) and gene specific primers (RPS14: 5’-
TCACCGCCCTACACATCAAACT-3’ and 5’-CTGCGAGTGCTGTCAGAGG-3’; 
survivin:  5’-GGACCACCGCATCTCTACAT-3’ and 5’-
GACAGAAAGGAAAGCGCAAC-3’; bcl-2:  
5’-CAGTTGGGCAACAGAGAACCAT-3’ and 5’-
AGCCCTTGTCCCCAATTTGGAA-3’; bax: 5’-
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 7 
CGAGTGGCAGCTGACATGTTTT-3’ and 5’-
TGAGGCAGGTGAATCGCTTGAA-3’). PCR amplifications included a standard 
curve for each amplified gene in order to extrapolate transcript amounts from the Ct 
values. Relative transcript expression was normalized to that of RPS14 mRNA [20]. 
For miR-218 detection, 50 ng total RNA was reverse transcribed using a TaqMan 
MicroRNA Reverse Transcription kit and real-time quantitative PCR was performed 
using TaqMan miR and U6 RNA (used as a normalizer) assays (Life Technologies, 
Grand Island, NY, USA) following the manufacturer’s instructions [19]. A customary 
miRNA expression profiling using a TaqMan® Array Human MicroRNA Cards 
containing 384 human miRNAs was performed by Life Technologies (Beijing, 
China).  
 
Protein extraction and western blotting 
 
A modified RIPA buffer (50 mM Tris–HCl, 150 mM NaCl, 0.25 % SDS, 1 % Triton 
X-100, 0.25 % sodiumdeoxycholate, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol) 
with protease inhibitor cocktail (Sigma, St. Louis, MO, USA) was used for protein 
isolation. Protein concentrations were determined using the BCA Protein Assay Kit 
(Pierce, Rockford, IL, USA). Cell lysates containing 50 μg of total protein were 
resolved on 12 % polyacrylamide gels and transferred to nitrocellulose membranes 
(Millipore, Billerica, MA, USA) and blocked with 5 % blotting grade milk (Bio-Rad, 
Hercules, CA, USA) in PBST (0.1 % Tween 20 in PBS). Then membranes were 
incubated with primary antibodies (D16H11 for GAPDH, 71G4B7 for survivin, 
D2E11 for Bax and 50E3 for Bcl-2; all 1:1000) at 4°C overnight, followed by HRP-
conjugated secondary antibodies at 1:2000 dilution for 2 h at room temperature. All 
antibodies were purchased from Cell Signalling Technology (Danvers, MA, USA). 
Signals were visualized using SuperSignal West Pico Chemiluminescent Substrate 
(PIERCE, Rockford, IL, USA) according to the manufacturer’s instructions. 
 
Annexin V staining 
 
Cell apoptosis was measured using an annexin V-FITC apoptosis detection kit 
(Becton–Dickinson, San Diego, CA) essentially as described [21]. Briefly, cells 
(2×10
5) were incubated with taxol (0.25 μM for MCF-7/A02 and 2.5 nM for 
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CALDOX) for 48 h, washed twice and resuspended in 100 μl binding buffer, followed 
by staining with both 5 μl annexin V and 5 μl propidium iodide in the dark at room 
temperature for 15 min. Cells fluorescence was assayed by flow cytometry using a 
FACSCalibur flow cytometer (Becton–Dickinson, San Jose, CA). 
 
Caspase activity 
 
Cells (1×10
4
) were incubated with taxol in 96-well plates for 24 h, and the caspase-
3/7 and caspase-9 activities measured using Caspase-Glo® 3/7 Assay and Caspase-
Glo® 9 Assay Kits, respectively (Promega, Madison, WI, USA) following the 
manufacturer’s protocol. Fluorescence was measured using a GloMaxTM 20/20 
Luminometer (Promega, Madison, WI, USA). 
 
In vivo tumor assay 
 
Cells (5×10
6
) were resuspended in a total volume of 100 μl containing 50% Matrigel 
(BD Biosciences, San Jose, CA, USA) in PBS and injected into the mammary fat pad 
of 4–5 week-old nude mice. Tumor sizes were measured every three days in two 
dimensions using a caliper, and the tumor volume was calculated with the following 
formula: tumor volume (mm
3
) = 0.5×ab
2
 ( a and b being the longest and shortest 
diameters of the tumor, respectively). Twenty-one days after cell injection, tumor-
bearing mice were randomly divided into different groups (five animals/group ) for 
taxol treatment (2.5 mg/kg) or control (saline). Drug was injected every three days 
and tumor volume was monitored until the mice were sacrificed in a humane manner. 
Tumors were collected, RNA isolated using a mirVana miRNA Isolation Kit (Life 
Technologies, Grand Island, NY, USA) following manufacturer’s protocol and gene 
expression analysis performed by qPCR. All animal studies were performed at the 
National Institutes of Health (Tianjin cancer hospital) in accordance with guidelines 
under Institutional Animal Care and Use Committee (IACUC) and approved by the 
Committee on the Ethics of Animal Experiments of the Tianjin Cancer Hospital. 
 
Statistical analysis 
 
A t test was used when comparing samples. Statistical significance was considered 
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when P < 0.05. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 10 
Results 
 
MicroRNA signature of drug resistant breast cancer cells  
 
Two breast cancer cell lines, MCF-7/A02 and CALDOX, were derived from the 
chemosensitive cell lines MCF-7 and Cal51, respectively, by their resistance to 
doxorubicin, a common chemotherapeutic used in many cancer treatments  [18, 21]. 
To determine the identity of miRNAs that might contribute to the drug resistant 
phenotype, a miRNA array was employed to characterize the miRNA signature of 
MCF-7/A02 cells. We selected those miRNAs differentially expressed at least 5 fold 
and with P value <0.05 between the sensitive MCF7 and drug resistant MCF-7/A02 
cells. A total of 16 miRNAs fullfilled these criteria, 9 being up-regulated and 7 down-
regulated in MCF-7/A02 cells (Table 1). Some miRNAs, such as miR-130b, were up-
regulated up to 17 fold in drug resistant MCF-7/A02 cells, whereas others, such as 
miR-7-1* or  miR-183* , were down-regulated 20 fold. This drug resistant miRNA 
signature obtained in MCF-7/A02 cells was tested in CALDOX cells by determining 
the expression levels of all these miRNAs using qPCR. We found that miR-218 was 
also down-regulated in CALDOX cells by approximately 3 fold. (Fig. 1A,B). 
 
Over-expression of miR-218 restores drug sensitivity 
 
As miR-218 is down-regulated in drug resistant breast cancer cell lines, we 
hypothesized that if it would contribute to the drug resistant phenotype, its 
experimental over-expression might restore drug sensitivity. To test this hypothesis, 
we generated stable MCF-7/A02 and CALDOX cells over-expressing miR-218 by 
lentiviral transfection  (MCF-7/A02-miR-218 and CALDOX-miR-218, respectively). 
Cells transfected with the empty vector (MCF-7/A02-miRVec and CALDOX-miRVec) 
were used as control. MiR-218 expression was up-regulated 6 fold in MCF-7/A02-
miR-218 cells and 4 fold in CALDOX-miR-218 cells (Fig. 2A). Drug sensitivity 
assays indicated that the taxol IC50 values of miR-218 over-expressing cells 
decreased between 55 and 80% (79.2% in MCF-7/A02-miR-218 cells and 55.6% in 
CALDOX-miR-218 cells). Equally, miR-218 over-expressing cells were more 
sensitive to doxorubicin, the IC50 values of miR-218 over-expressing cells decreased 
between 62% and 70% (69.3% in MCF-7/A02-miR-218 cells and 62.8% in 
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CALDOX-miR-218 cells) (Fig. 2B, Supplementary Figure S1A.). Moreover, to 
evaluate the efficacy of miR-218 over-expression on drug resistance, we treated cells 
with drugs and let them to proliferate for one week. Crystal violet staining was used 
as a surrogate for cell mass in this assay [19]. MiR-218 restoration slightly decreased 
cell proliferation in absence of drug. However, it impaired proliferation to a higher 
extent in the presence of both doxorubicin and taxol (reduction between 64% and 
72%, Fig. 2C, Supplementary Figure S1B). Thus, the over-expression of miR-218 
restores sensitivity to doxorubicin and taxol in drug resistant breast cancer cells. 
 
MiR-218 targets survivin in breast cancer cells 
 
MiR-218 targets survivin in cervical [22] and nasopharyngeal cancer [23] (Fig. 3A). 
As survivin has been identified as an anti-apoptosis gene in a variety of cancers 
[24,25], and may partially lead to drug resistance [26,27], we hypothesized that a 
negative correlation should exist between miR-218 and survivin expression. Indeed, 
drug-resistant MCF-7/A02 and CALDOX cells, which express low levels of miR-218 
(Fig. 1A),  showed abundant survivin expression both at mRNA and protein levels 
(Fig. 3B). When miR-218 expression was experimentally restored in drug resistant 
cells (Fig. 2A), a decrease in survivin expression (both mRNA and protein) was 
observed (Fig. 3C). 
 To further verify that survivin mRNA was a target of miR-218 in breast cancer 
cells, we transiently transfected cells over-expressing miR-218 with a luciferase 
reporter with or without the 3’-UTR of survivin (pMirTarget-survivin and pMirTarget-
ev, respectively) together with a Renilla luciferase expressing plasmid to normalize 
for transfection efficiency. We hypothesized that luciferase expression would decrease 
in cells over-expressing miR-218 in those cells transfected with the reporter plasmid 
incorporating survivin 3'-UTR but not in the control. Indeed, an approximately 50% 
reduction in luciferase expression was observed in both MCF-7/A02-miR-218 versus 
MCF-7/A02-miRVec and CALDOX-miR-218 versus CALDOX-miRVec cells when 
transfected with pMirTarget-survivin. However, no changes in luciferase expression 
were observed in the same cells when transfected with the pMiRTarget-ev control 
vector (Fig. 3D). Thus, miR-218 binds survivin 3'-UTR and decreases its expression 
in breast cancer cells.  
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MiR-218 over-expression promotes cell apoptosis, induces caspase activity and 
modulates apoptosis-related proteins 
 
As survivin inhibits cell apoptosis in prostate, ovarian, and renal carcinomas [28-30], 
we asked whether miR-218 over-expression could regulate apoptosis in breast cancer 
cells. For this we used taxol, a widely used microtubule poison known to activate 
mainly the intrinsic apoptotic pathway [31].  Annexin V staining indicated that in both 
drug resistant cells ectopic expression of miR-218 increased the percentage of cells 
undergoing apoptosis after taxol treatment (Fig. 4A, B). As CALDOX cells are more 
sensitive to taxol than MCF-7/A02 cells (Fig. 2B) the concentration of taxol used was 
0.25 μM for MCF-7/A02 and 2.5 nM for CALDOX cells. As the dot plots indicate, 
approximately 30% of MCF-7/A02-miR-218 cells were in the early stages of 
apoptosis (positive annexin V and negative propidium iodide), whereas approximately 
38% of CALDOX-miR-218 cells were already in the late stage of apoptosis after 48 h 
taxol treatment (positive for both annexin V and propidium iodide, Fig. 3A).  
 Measurement of caspase activation confirmed the results obtained with 
annexin V. Both caspase 9 and caspase 3/7 activities increased between 1 and 2 fold 
after taxol treatment in drug resistant cells over-expressing miR-218 when compared 
with the control cells expressing the empty vector (Fig. 3C). As the induction of 
apoptotic cell death could be partly due to alteration of pro-survival and pro-apoptotic 
proteins, we evaluated the expression level of bcl-2 (pro-survival) and bax (pro-
apototic) both at the mRNA and protein levels. Drug resistant cells over-expressing 
miR-218 showed decreased mRNA (1-2 fold) and protein expression of bcl-2 (Fig. 4D, 
E). Although not changed at mRNA level (Fig. 4D), pro-apoptotic bax expression was 
up-regulated in MCF-7/A02-miR-218 cells whereas CALDOX –miR-218 cells only 
showed slightly higher protein levels than control cells carrying the empty vector (Fig. 
4E). Thus, ectopic expression of miR-218 in drug resistant breast cancer cells restores 
doxorubicin and taxol sensitivity by promoting apoptosis. 
 
Suppression of survivin mimics the sensitization to taxol by miR-218 
 
To examine whether the phenotype observed after miR-218 over-expression was due 
to down-regulation of survivin, we knocked-down survivin mRNA in drug resistant 
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cells by RNA interference. Survivin mRNA was down-regulated by approximately 
60% in both drug resistant cells when transfected with a siRNA targeting survivin 
(Fig. 5A). A similar decrease was observed when survivin protein expression was 
determined by western blots (Fig. 5B). The decrease in survivin was accompanied by 
a resensitization of drug resistant MCF-7/A02 and CALDOX cells to taxol with a 
reduction in the IC50 of approximately 40% in the former and 55% in the latter (Fig. 
5C).  Measurement of caspase-3/7 and caspase-9 activities indicated an increase after 
taxol treatement in both drug resistant cells when transfected with siRNA survivin in 
comparison with siRNA control (Fig. 5C). In addition, knock-down of survivin 
resulted in down-regulation of bcl-2 and up-regulation of bax mRNAs (Fig. 5E). Thus, 
suppression of survivin mimics the phenotype obtained by miR-218 over-expression. 
 
MiR-218 suppresses tumor growth and reverses chemoresistance of MCF-7/A02 and 
CALDOX through targeting survivin in vivo 
 
In order to assess whether the resensitization of drug resistant cells observed in vitro 
upon over-expression of miR-218 (Fig. 2) could be reproduced in vivo, we used a 
xenograft model. MCF-7/A02-miRVec, MCF-7/A02-miR-218, CALDOX-miRVec 
and CALDX-miR-218 cells were injected into the mammary fat pad of nude mice and 
tumor size were monitored every 3 days from the time when they were apparent (day 
6) up to day 48 post-implantation. Compared with the control group, (miRVec), tumor 
growth in the miR-218 group was significantly reduced (from approximately 600 
mm
3
 to approximately 400 mm
3
). Taxol treatment, that started at day 21 and was 
repeated every three days, was more effective in tumors derived from cells over-
expressing miR-218 than in those from control cells (Fig. 6A). Consistent with tumor 
volumes, tumor weights of animals sacrificed at day 48 post-implantation were lighter 
in the miR-218 than miRVec group and decreased further after taxol treatment (Fig. 
6B). As expected, tumors generated from miR-218-overexpressed cells had a higher 
expression of miR-218 and lower expression of survivin than tumors generated from 
control cells (Fig. 6C). Thus, miR-218 acts as a tumor suppressor and is effective in 
sensitizing breast cancer drug resistant cells to taxol in vivo. 
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Discussion 
Chemotherapeutics are widely used in the treatment of various solid tumors. However, 
the appearance of drug resistance is a considerable obstacle for effective cancer 
therapy. Dysregulation of miRNAs has been found in nearly all types of human 
malignancies [7]. In order to characterize the role of miRNAs in breast cancer drug 
resistance, we applied high-throughput miRNA microarray analysis to obtain a 
miRNA signature of drug resistant MCF-7/A02 breast cancer cells. These cells have 
been generated from MCF-7 cells, an estrogen receptor-positive line, by exposure to 
doxorubicin and they are resistant to drugs such as taxol, etoposide, vincristine and 
mitoxantrone [21].  We identified 16 miRNAs differentially regulated (9 up and 7 
down) in MCF-7/A02 cells, including miR-130b, miR-19a, miR-222, miR-218, miR-
425 and miR-452. Some of these miRNAs have been associated with chemoresistance 
in several carcinomas. MiR-222 confers dexamethasone resistance in human multiple 
myeloma and tamoxifen resistance in breast cancer by targeting CDKN1B (alias p27, 
Kip1) [32], miR-19a regulates drug resistance in gastric and breast cancer cells 
through targeting PTEN [33,34], and deletion of miR-15a contributes to drug 
resistance in chronic lymphocytic leukemia, by targeting Mcl1 [35,36], and 
osteosarcoma through down-regulation of CCND1 [32].   
 In order to test the functionality of the drug resistance signature, we measured 
the expression of these 16 miRNAs in CALDOX cells. These drug resistant cells are 
derived from Cal51, a triple negative breast cancer cell line, by exposure to a single 
concentration of doxorubicin (0.4 µM) and show decrease sensitivity to doxorubicin, 
etoposide and mitoxantrone [18]. Only miR-218 was also down-regulated in these 
drug resistant cells. Since MCF-7/A02 and CALDOX have different resistance 
profiles and are derived from two different type of breast cancer cells, it is very likely 
that miR-218 down-regulation plays a role in drug resistance. 
 MiR-218 dysregulation may be a common occurrence in tumorigenesis [37], 
and plays a critical function in tumor invasion and metastasis progression in a variety 
of malignancies, including breast cancer [38]. In addition, miR-218 has been found to 
modulate chemosensitivity in human gastric cancer cells [39], and restoration of miR-
218 expression increases cisplatin sensitivity, and induces apoptosis, in cisplatin-
resistant MCF-7 cells by targeting BRCA1 [17]. We find that experimental over-
expression of miR-218 in both MCF-7/A02 and CALDOX cells restores short-term 
sensitivity and long-term proliferation in the presence of doxorubicin and taxol. 
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MiRNAs bind the 3'-UTR of target mRNAs repressing their translation and leading to 
mRNA degradation. As binding to target sequences is not very stringent, a single 
miRNA may regulate the expression of many different mRNAs. MiR-218 binds to a 
variety of targets, such as IKK-β, ECOP, BMI1, Rictor, BRCA1, Robo1, SLIT2, and 
PXN in different cell systems [12, 23]. In nasopharayngeal and cervical cancinoma,  
miR-218 targets survivin and contributes to cell migration and invasion [22,23]. Our 
results indicate that in both estrogen receptor-positive and triple negative breast 
cancer cells, miR-218 also targets survivin.   
 Survivin (encoded by BIRC5) is the smallest member of the inhibitor of 
apoptosis (IAP) protein family which comprises eight members. Although survivin 
was initially discovered as an anti-apoptotic protein due to its caspase inhibition 
activity, it also serves as an indispensable regulator of cell mitosis [40]. Dysregulation 
of survivin is a key signature of many cancers, where it is over-expressed,  and is 
undetectable in normal differentiated tissues [41,42]. Survivin carries out its anti-
apoptotic function through inhibition of caspase-9, for which the presence of a helper 
protein, hepatitis B X-interacting protein (HBXIP), is necessary [24], and thus plays 
an important role in cancer drug resistance. As a consequence, survivin is a very 
promising biomarker for drug resistance [43]. Survivin dysregulation in human 
cancers can be the result of epigenetic mechanisms due to promoter methylation [44]. 
In addition,  several survivin-targeting miRNAs have been described in different 
cancers [45], including miR-218 in nasopharyngeal cancer [23].  Here we present data 
indicating that miR-218 targets survivin in breast cancer cells leading to an increase in 
apoptosis, and restoration of drug sensitivity in drug-resistant cells. 
 MiR-218 is down-regulated in many tumors, including breast cancer, and is 
involved in cancer initiation and development. It is thus considered as a tumor 
suppressor. Our xenograft results confirm that miR-218 acts as a tumor suppressor 
and modulator of drug response, via survivin,  in breast cancer. As lung cancer 
patients with low miR-218 expression have shorter overall survival rates than patients 
with high miR-218 expression [46], the potential clinical applications of miR-218 in 
breast cancer deserve further investigation. For survivin, YM155, an agent identified 
after a chemical library screening, has a potent suppressive activity against the 
survivin promoter [47], and it is the only small molecule specifially blocking survivin 
in humans [48]. Targeting miR-218 and survivin may thus provide a potential strategy 
for reversing drug resistance in breast cancer cells. Further studies using preclinical 
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animal models are necessary to confirm whether or not the proposed approach has 
potential value for clinical trials. 
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Fig 1 MiR-218 is down-regulated in drug resistant breast cancer cells. MiR-218 
expression was determined by qPCR in pairs of drug-sensitive and resistant A) MCF-
7, B) Cal51 cells. MiR expression was normalized to that of U6 RNA. Data represent 
the average ± SD of three independent experiments. * P<0.05 
 
Fig 2 MiR-218 over-expression restores drug sensitivity. Drug resistant MCF-7/A02 
and CALDOX cells were stably transfected with a lentivirus carrying an expression 
vector for miR-218, generating MCF-7/A02-miR-218 and CALDOX-miR-218 cells, 
respectively. Control cells, MCF-7/A02-miRVec and CALDOX-miRVec, were 
transfected with the empty vector. (A) Expression of miR-218 was determined by 
qPCR and was normalized to U6 RNA expression. (B) Doxorubicin, left panels, and 
taxol, right panels, IC50 values. (C) Cells were treated with doxorubicin (15 μM for 
MCF-7/A02 and 1 μM for CALDOX) and taxol (0.25 μM for MCF-7/A02 and 2.5 
nM for CALDOX) for seven days and the cells stained with crystal violet. Dye was 
solubilized and the OD592 nm determined. Data represent the average ± SD of three 
independent experiments. * P < 0.05 
 
Fig 3 Identification of survivin as a direct target of miR-218 in breast cancer cells. (A) 
Annealing of miR-218 to survivin (BIRC5) 3’-UTR according to the microRNA.org 
database [49]. (B) Survivin expression at mRNA (qPCR; upper panel) and protein 
levels (western blot; lower panel) in sensitive and drug resistant breast cancer cells. 
(C) Expression level of survivin expression in drug resistant cells after stable 
expression of miR-218 or miRVec vector control at mRNA (qPCR; upper panel) and 
protein levels (western blot; lower panel). (D) MiR-218 targets survivin mRNA. 
Normalized firefly luciferase activity from the reporter with the survivin 3’-UTR 
(pMirTarget-survivin) or the empty vector (pMirTarget-ev) after transient transfection 
into cells over-expressing miR-218 or control (miRVec) cells. In all cases cells were 
co-transfected with a Renilla luciferase expression vector to normalize for transfection 
efficiency. Numerical data show the average ± SD of at least three experiments (* P < 
0.05) and the immunoblot shows a representative of at least three replicates 
 
Fig 4 MiR-218 restores drug sensitivity by activating apoptosis in breast cancer cells. 
Cells were treated with taxol (0.25 μM for MCF-7/A02 series and 2.5 nM for 
CALDOX series) for 48 h. A) Detection of annexin V / propidium iodide staining by 
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flow cytometry. Cells in the upper right (UR) quadrant are at the late apoptotic stage, 
whereas those in the lower right (LR) quadrant are early apoptotic. Plots shown are 
representative of three independent experiments. B) Quantification of cell death by 
flow cytometry. Data show the average percentage of annexin V positive cells ± SD of 
three independent experiments. (C) Caspase-3/7 (upper histograms) and caspase-9 
(lower histograms) activity of drug resistant cells after taxol treatment. (D, E) 
Expression levels of bcl-2 and bax in transfected drug resistant cells were determined 
by qPCR (D) and western blotting (E). Numerical data represent mean ± SD based on 
three independent experiments. *P < 0.05 and the immunoblot shows a representative 
of three replicates 
 
Fig 5 Down-regulation of survivin mimics miR-218 overexpression. 
Drug resistant MCF-7/A02 and CALDOX cells were transiently transfected with 
siRNAs targeting survivin (siSurvivin) or a scrambled siRNA (siControl) and survivin 
expression determined by qPCR (A) after 2 days and western blotting (B) after 3 days. 
(C) Taxol IC50 in both sets of cells. (D) Caspase 3/7 (upper panels) and caspase 9 
(lower panels) were determined in transfected cells after 24h of treatment with taxol. 
(E) Bcl-2 and bax mRNA analysis determined by qPCR. Numerical data represents 
the average ± SD of three independent experiments. The immunoblot is a 
representative of three independent experiments 
 
Fig 6 MiR-218 acts as a tumor suppressor and resensitizes breast cancer drug resistant 
cells to taxol in tumor xenografts. Drug resistant breast cancer cells stably expressing 
miR-218 or miRVec control were subcutaneously injected into the fat pad of nude 
mice (five per group). Twenty-one days after implantation, mice were randomly split 
in two groups and treated either with vehicle or taxol (2.5 mg/kg) every three days 
until they were sacrificed 48 days after implantation, when xenografts were removed. 
(A) Size of MCF-7/A02 or CALDOX xenograft tumors after treatment with saline or 
taxol. Data are mean tumor size ± SD of five tumors per group. (B) Tumor weight 48 
days after implantation in mice treated with saline or taxol. Data indicates tumor 
weight in individual mice (dots) and the mean values (line) in five mice per group. (C) 
RNA was isolated from tumors 48 days post-implantation and miR-218 and survivin 
mRNA expression determined by qPCR. The individual tumor expression data (dots) 
and the mean values (line) are indicated  
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Table 1 MiRNA drug resistance signature of MCF-7/A02 cells  
 
Gene name Fold change
a
 
hsa-miR-130b 17.495 
hsa-miR-135a* 17.081 
hsa-miR-942 15.526 
hsa-miR-19a 13.377 
hsa-miR-9 12.962 
hsa-miR-222 12.362 
hsa-miR-20a* 6.883 
hsa-miR-572 6.506 
hsa-miR-126* 5.421 
hsa-miR-7-1* 0.057 
hsa-miR-183* 0.067 
hsa-miR-15a 0.078 
hsa-miR-425 0.086 
hsa-miR-99b* 0.104 
hsa-miR-218 0.137 
hsa-miR-452 0.174 
a
ratio of expression between MCF-7/A02 and MCF-7 cells 
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